MX2023000806A - Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. - Google Patents
Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos.Info
- Publication number
- MX2023000806A MX2023000806A MX2023000806A MX2023000806A MX2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A MX 2023000806 A MX2023000806 A MX 2023000806A
- Authority
- MX
- Mexico
- Prior art keywords
- lipid
- methods
- lipid nanoparticles
- novel formulation
- reduced sizes
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 7
- 238000009472 formulation Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title 1
- 108091033319 polynucleotide Proteins 0.000 title 1
- 239000002157 polynucleotide Substances 0.000 title 1
- 108020005202 Viral DNA Proteins 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente se proporcionan formulaciones lipídicas de tamaño reducido, que comprenden un lípido y un vector no viral sin cápside (p. ej., ADNec), y métodos para producir dichas formulaciones lipídicas. Las partículas lipídicas (p. ej., nanopartículas lipídicas) de la descripción incluyen una formulación lipídica que puede usarse para administrar un vector de ADN no viral sin cápside en un sitio diana de interés (p. ej., célula, tejido, órgano y similares).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063053274P | 2020-07-17 | 2020-07-17 | |
US202163194620P | 2021-05-28 | 2021-05-28 | |
PCT/US2021/042033 WO2022016089A2 (en) | 2020-07-17 | 2021-07-16 | Methods for encapsulating polynucleotides into reduced sizes of lipid nanoparticles and novel formulation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000806A true MX2023000806A (es) | 2023-04-11 |
Family
ID=79555025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000806A MX2023000806A (es) | 2020-07-17 | 2021-07-16 | Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230320993A1 (es) |
EP (1) | EP4181948A2 (es) |
JP (1) | JP2023534043A (es) |
KR (1) | KR20230052895A (es) |
CN (1) | CN116437964A (es) |
AU (1) | AU2021307952A1 (es) |
CA (1) | CA3186033A1 (es) |
IL (1) | IL299896A (es) |
MX (1) | MX2023000806A (es) |
WO (1) | WO2022016089A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
RS65449B1 (sr) | 2018-10-09 | 2024-05-31 | The Univ Of British Columbia | Supstance i sistemi koji obuhvataju vezikule kompetentne za transfekciju bez organskih rastvarača i deterdženata i metode za to |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
WO2021195529A2 (en) * | 2020-03-27 | 2021-09-30 | Generation Bio Co. | Novel lipids and nanoparticle compositions thereof |
WO2022226008A2 (en) * | 2021-04-20 | 2022-10-27 | Generation Bio Co. | Cationic lipids and compositions thereof |
KR20230162973A (ko) * | 2021-05-28 | 2023-11-29 | 베이징 트리시젼바이오 테라퓨틱스 인코퍼레이티드 | 지질 화합물 및 이의 핵산 전달에서의 응용 |
CN117642380A (zh) * | 2021-06-14 | 2024-03-01 | 世代生物公司 | 阳离子脂质及其组合物 |
CN118201605A (zh) * | 2021-10-25 | 2024-06-14 | 杜克大学 | 基于poegma的脂质纳米粒子 |
WO2023190166A1 (ja) * | 2022-03-28 | 2023-10-05 | 日油株式会社 | ジスルフィド結合を有するカチオン性脂質、これを含む脂質膜構造体、これらのいずれかを含む核酸導入剤及び医薬品組成物、核酸を細胞又は標的細胞内へ導入する方法、及び細胞医薬品の製造方法 |
CN114685784B (zh) * | 2022-04-26 | 2023-09-15 | 北京清科胜因生物科技有限公司 | 一种用于核酸递送的聚(2-噁唑啉)脂质与脂质纳米颗粒及应用 |
WO2023239756A1 (en) * | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
CN115105584B (zh) * | 2022-06-28 | 2023-03-31 | 长春生物制品研究所有限责任公司 | 一种卡式瓶多剂量笔式注射组合包装的干扰素注射液 |
WO2024037577A1 (en) * | 2022-08-18 | 2024-02-22 | Suzhou Abogen Biosciences Co., Ltd. | Composition of lipid nanoparticles |
WO2024072908A1 (en) * | 2022-09-27 | 2024-04-04 | Reinvigoron Theratech, Inc. | Compounds with cleavable disulfide moieties |
KR20240066975A (ko) * | 2022-11-08 | 2024-05-16 | 주식회사 삼양홀딩스 | 양이온성 지질 및 이의 제조방법 |
WO2024119103A1 (en) | 2022-12-01 | 2024-06-06 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013237874B2 (en) * | 2012-03-29 | 2018-01-18 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
WO2019188867A1 (ja) * | 2018-03-27 | 2019-10-03 | 日油株式会社 | 細胞内動態を改善した新規カチオン性脂質 |
WO2021195529A2 (en) * | 2020-03-27 | 2021-09-30 | Generation Bio Co. | Novel lipids and nanoparticle compositions thereof |
-
2021
- 2021-07-16 AU AU2021307952A patent/AU2021307952A1/en active Pending
- 2021-07-16 KR KR1020237005643A patent/KR20230052895A/ko unknown
- 2021-07-16 IL IL299896A patent/IL299896A/en unknown
- 2021-07-16 JP JP2023502945A patent/JP2023534043A/ja active Pending
- 2021-07-16 CN CN202180063144.XA patent/CN116437964A/zh active Pending
- 2021-07-16 EP EP21842533.8A patent/EP4181948A2/en active Pending
- 2021-07-16 WO PCT/US2021/042033 patent/WO2022016089A2/en unknown
- 2021-07-16 MX MX2023000806A patent/MX2023000806A/es unknown
- 2021-07-16 US US18/015,575 patent/US20230320993A1/en active Pending
- 2021-07-16 CA CA3186033A patent/CA3186033A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4181948A2 (en) | 2023-05-24 |
KR20230052895A (ko) | 2023-04-20 |
JP2023534043A (ja) | 2023-08-07 |
WO2022016089A3 (en) | 2022-03-03 |
AU2021307952A1 (en) | 2023-03-02 |
CA3186033A1 (en) | 2022-01-20 |
IL299896A (en) | 2023-03-01 |
US20230320993A1 (en) | 2023-10-12 |
CN116437964A (zh) | 2023-07-14 |
WO2022016089A2 (en) | 2022-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023000806A (es) | Métodos para encapsular polinucleótidos en tamaños reducidos de nanopartículas lipídicas y formulación novedosa de estos. | |
Badieyan et al. | Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration | |
EP3492597A3 (en) | Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer | |
Wang et al. | Biomineralization-based virus shell-engineering: towards neutralization escape and tropism expansion | |
MX2023005397A (es) | Escision de secuencias de acido nucleico retrovirales. | |
Kim et al. | Efficacy of mesoporous silica nanoparticles in delivering BMP‐2 plasmid DNA for in vitro osteogenic stimulation of mesenchymal stem cells | |
EP4338799A3 (en) | Tumor infiltrating lymphocytes and methods of therapy | |
BR112022007481A2 (pt) | Lipídios ionizáveis e composições de nanopartículas dos mesmos | |
CO2017001921A2 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
MX2021005389A (es) | Formulaciones de nanoparticulas lipidicas. | |
BR112018004108A2 (pt) | ochrobactrum haywardense h1 isolada, ochrobactrum haywardense h1, método para produzir uma célula vegetal transformada, kit e vetor | |
BR212016030926U2 (pt) | conjugados de alvo e partículas e formulações dos mesmos | |
TW201536340A (zh) | 含有脂質肽型化合物之條狀基材 | |
WO2017156311A3 (en) | Combination vectors and methods for treating cancer | |
WO2007037653A8 (en) | Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer | |
WO2021195529A3 (en) | Novel lipids and nanoparticle compositions thereof | |
US20170157036A1 (en) | Microneedle-based transdermal delivery system and method of making same | |
García-Quiroz et al. | The interaction of human papillomavirus infection and prostaglandin E2 signaling in carcinogenesis: a focus on cervical cancer therapeutics | |
EP3538116A1 (en) | Microneedle-based transdermal delivery system and method of making same | |
Zhang et al. | HSA-templated self-generation of gold nanoparticles for tumor vaccine delivery and combinational therapy | |
MX2020006476A (es) | Vacuna contra el virus de lassa. | |
JP7303561B2 (ja) | キャプシドユニットによってカプセル化された核酸オリガミ構造 | |
Wu et al. | Dual-driven nanomotors enable tumor penetration and hypoxia alleviation for calcium overload-photo-immunotherapy against colorectal cancer | |
Ali et al. | Surface decoration of selenium nanoparticles by proteins from the culinary-medicinal shiitake mushroom, Lentinus edodes (Agaricomycetes), for enhanced fibrinolytic activity | |
CN103920161A (zh) | 一种在细胞膜微囊中高效装载药物的方法 |